Generic Wegovy Availability
Last updated on Nov 6, 2024.
Wegovy is a brand name of semaglutide, approved by the FDA in the following formulation(s):
WEGOVY (semaglutide - solution;subcutaneous)
-
Manufacturer: NOVO
Approval date: June 4, 2021
Strength(s): 0.25MG/0.5ML (0.25MG/0.5ML) [RLD], 0.5MG/0.5ML (0.5MG/0.5ML) [RLD], 1MG/0.5ML (1MG/0.5ML) [RLD], 1.7MG/0.75ML (1.7MG/0.75ML) [RLD], 2.4MG/0.75ML (2.4MG/0.75ML) [RLD]
Has a generic version of Wegovy been approved?
No. There is currently no therapeutically equivalent version of Wegovy available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Wegovy. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
GLP-1 compositions and uses thereof
Patent 10,888,605
Issued: January 12, 2021
Inventor(s): Moeller Eva Horn & Soerensen Michael Duelund & Lundqvist Joakim
Assignee(s): Novo Nordisk A/SThe present invention relates to pharmaceutical compositions of the GLP-1 peptide semaglutide comprising no more than 0.01% (w/w) phenol, their preparation, kits comprising such compositions as well as uses thereof.
Patent expiration dates:
- August 24, 2038✓✓
- August 24, 2038
-
Patent 11,318,191
Patent expiration dates:
- February 17, 2041✓✓
- February 17, 2041
-
Patent 11,752,198
Patent expiration dates:
- August 24, 2038✓✓
- August 24, 2038
-
Patent 12,029,779
Patent expiration dates:
- October 10, 2038✓
- October 10, 2038
-
Acylated GLP-1 compounds
Patent 8,129,343
Issued: March 6, 2012
Inventor(s): Lau Jesper & Bloch Paw & Hansen Thomas Kruse
Assignee(s): Novo Nordisk A/SProtracted GLP-1 compounds and therapeutic uses thereof.
Patent expiration dates:
- December 5, 2031✓✓
- December 5, 2031
-
Acylated GLP-1 compounds
Patent 8,536,122
Issued: September 17, 2013
Inventor(s): Lau Jesper & Doerwald Florencio Zaragoza & Bloch Paw & Hansen Thomas Kruse
Assignee(s): Novo Nordisk A/SProtracted GLP-1 compounds and therapeutic uses thereof.
Patent expiration dates:
- March 20, 2026✓✓
- March 20, 2026
-
Use of long-acting GLP-1 peptides
Patent 9,764,003
Issued: September 19, 2017
Inventor(s): Jensen Christine B.
Assignee(s): Novo Nordisk A/SThe invention relates to use of long-acting GLP-1 peptides in certain dosage regimes for the treatment of type 2 diabetes, obesity, etc.
Patent expiration dates:
- June 21, 2033✓
- June 21, 2033
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- June 4, 2024 - NEW PRODUCT
- December 23, 2025 - NEW PATIENT POPULATION
- July 21, 2026 - USE OF SEMAGLUTIDE 1.7 MG SUBCUTANEOUS WEEKLY AS AN ADDITIONAL MAINTENANCE DOSE
- March 8, 2027 - IN COMBINATION WITH A REDUCED CALORIE DIET AND INCREASED PHYSICAL ACTIVITY TO REDUCE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (CARDIOVASCULAR DEATH, NON-FATAL MYOCARDIAL INFARCTION, OR NON-FATAL STROKE) IN ADULTS WITH ESTABLISHED CARDIOVASCULAR DIS
More about Wegovy (semaglutide)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (403)
- Drug images
- Latest FDA alerts (3)
- Side effects
- Dosage information
- During pregnancy
- Support group
- FDA approval history
- Drug class: Incretin Mimetics (GLP-1 Agonists)
- Breastfeeding
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
